What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008
Bal�s Disease Showing Benign Clinical Course and Co-Existence with Multiple Sclerosis-Like Lesions in Chinese
Multiple Sclerosis 14:418-424, Wang,C.,et al, 2008
Unexpected Multiple Sclerosis: Follow-Up of 30 Patients With Magnetic Resonance Imaging and Clinical Conversion Profile
JNNP 79:195-198,112, Lebrun,C.,et al, 2008
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Diagnosis and Management of Motor Neurone Disease
BMJ 336:658-662, McDermott,C.J. &Shaw,P.J., 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Do Oligoclonal Bands Add Information to MRI in First Attacks of Multiple Sclerosis?
Neurol 70:1079-1083,1059, Tintore,M.,et al, 2008
Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008
NMO-IgG Predicts the Outcome of Recurrent Optic Neuritis
Neurol 70:2197-2200, Matiello,M.,et al, 2008
Sudden Falls Due to Seizure-Induced Cardiac Asystole in Drug-Resistant Focal Epilepsy
Neurol 70:1933-1935, Rubboli,G.,et al, 2008
Tick-Borne Encephalitis
Lancet 371:1861-1871, Lindquist,L. &Vapalahti,O., 2008
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
NMO Antibody-Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis
Arch Ophthalmol 126:566-570, Dinkin,M.J.,et al, 2008
Gray Matter Atrophy in Multiple Sclerosis: A Longitudinal Study
Ann Neurol 64:255-265,230, Fisher,E.,et al, 2008
Curable Cause of Paraplegia: Spinal Dural Arteriovenous Fistulae
Stroke 39:2756-2759, Aghakhani,N.,et al, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
Hyperdense Internal Carotid Artery Sign: A CT Sign of Acute Ischemia
Stroke 39:2011-2016, Ozdemir,O.,et al, 2008
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Percutaneous Clot Removal Devices in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Arch Neurol 65:1024-1030, Stead,L.G.,et al., 2008
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Four New Cases of Therapy-Related Acute Promyelocytic Leukemia After Mitoxantrone
Neurol 71:457-458, Bosca,I.,et al., 2008
Prediction of Functional Outcome in Patients With Primary Intracerebral Hemorrhage: The FUNC Score
Stroke 39:2304-2309, Rost,N.S.,et al., 2008
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Multiple Sclerosis and Cannabis: A Cognitive and Psychiatric Study
Neurol 71:164-169, Ghaffar,O. &Feinstein,A., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Finding NMO: Neuromyelitis Optica in Chidlren
Neurol 70:334-335, Levy,M.,et al, 2008
Mitoxantrone as Induction Treatment in aggressive Relapsing Remitting Multiple Sclerosis: Treatment Response Factors in a 5 Year Follow-up Observational Study of 100 Consecutive Patients
JNNP 79:52-56, Le Page,E.,et al, 2008
Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008
Brain Magnetic Resonance Imaging Abnormalities in Neuromyelitis Optica
Acta Neurol Scand 118:218-225, Li, Y.,et al, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Quantitative Assessment of Iron Accumulation in the Deep Gray Matter of Multiple Sclerosis by Magnetic Field Correlation Imaging
AJNR 28:1639-1644, Ge,Y.,et al, 2007
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Arch Neurol 64:1426-1432, de Seze,J.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Predictors of Fitness to Drive in People With Parkinson Disease
Neurol 69:1434-1441, Devos,H.,et al, 2007
The Incidence and Significance of Anti-Natalizumab Antibodies: Results from AFFIRM and SENTINEL
Neurol 69:1391-1403,1396, Calabresi,P.A.,et al, 2007
Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007
Long-Term Prognosis in Children With Neonatal Seizures: A Population-Based Study
Neurol 69:1816-1822, Ronen,G.M.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Treatment of Physicians With Epilepsy
Neurol 69:1374-1379, Allen,J.W. &Devinsky,O., 2007